Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1,937 Mln
Revenue (TTM)
$17 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.2 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
3.2
Industry P/E
--
EV/EBITDA
-6.5
Div. Yield
0 %
Debt to Equity
0.2
Book Value
$4.7
EPS
$-0.8
Face value
--
Shares outstanding
128,293,480
CFO
$-811.94 Mln
EBITDA
$-781.36 Mln
Net Profit
$-756.34 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Mesoblast - ADR
| -12.4 | -0.3 | -12.4 | 26.6 | 33.9 | -0.9 | -1.8 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Mesoblast - ADR
| -8.9 | 784.0 | -62.2 | -39.4 | -43.5 | 15.2 | 78.9 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Mesoblast - ADR
|
15.8 | 1,937.0 | 17.2 | -102.1 | -363.1 | -19 | -- | 3.2 |
| 3.4 | 311.8 | 73.2 | -67.8 | -55.3 | -65.5 | -- | 4.1 | |
| 20.5 | 1,088.5 | 0.5 | -147.4 | -29,734.7 | -150.3 | -- | 6.4 | |
| 29.8 | 1,904.4 | 1,112.2 | 320.9 | -17.8 | 10.5 | 5.2 | 0.5 | |
| 15.2 | 2,582.6 | 550.0 | 458.1 | -3.3 | 45.9 | 5.4 | 1.9 | |
| 16.9 | 1,115.4 | 321.1 | 2.4 | 1,727.2 | 1.1 | 400.3 | 3.9 | |
| 3.4 | 568.7 | 4.6 | -201.1 | -4,342.4 | -146.8 | -- | 5.3 | |
| 5.5 | 235.2 | 0.6 | -88.6 | -14,555.6 | -98.3 | -- | 4.7 | |
| 6.3 | 913.1 | 174.7 | -115.2 | 0.0 | -80.2 | -- | 7.4 | |
| 20.3 | 2,015.9 | 460.2 | -175.5 | -37.7 | -22.6 | -- | 2.8 |
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based... on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure; MPC-25-IC for the treatment or prevention of acute myocardial infarction; and Ryoncil for the treatment of pediatric SR-aGVHD; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia. Address: 55 Collins Street, Melbourne, VIC, Australia, 3000 Read more
Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director
Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)
Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director
Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)
Headquarters
Melbourne, VIC
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Mesoblast Limited - ADR is $15.80 (NASDAQ) as of 01-Apr-2026 16:00 EDT. Mesoblast Limited - ADR has given a return of 33.91% in the last 3 years.
Since, TTM earnings of Mesoblast Limited - ADR is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-13.58
|
2.32
|
|
2024
|
-8.69
|
1.59
|
|
2023
|
-4.50
|
0.73
|
|
2022
|
-1.58
|
0.29
|
|
2021
|
-4.90
|
0.83
|
The 52-week high and low of Mesoblast Limited - ADR are Rs 21.50 and Rs 9.61 as of 02-Apr-2026.
Mesoblast Limited - ADR has a market capitalisation of $ 1,937 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Mesoblast Limited - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.42
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.